Andrea Mosca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1207393/publications.pdf

Version: 2024-02-01

49 papers	2,340 citations	393982 19 h-index	205818 48 g-index
52 all docs	52 docs citations	52 times ranked	2281 citing authors

#	Article	IF	Citations
1	IFCC Reference System for Measurement of Hemoglobin A1c in Human Blood and the National Standardization Schemes in the United States, Japan, and Sweden: A Method-Comparison Study. Clinical Chemistry, 2004, 50, 166-174.	1.5	587
2	Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood. Clinical Chemistry and Laboratory Medicine, 2002, 40, 78-89.	1.4	525
3	The IFCC Reference Measurement System for HbA1c: A 6-Year Progress Report. Clinical Chemistry, 2008, 54, 240-248.	1.5	169
4	Reference Intervals for Hemoglobin A1c in Pregnant Women: Data from an Italian Multicenter Study. Clinical Chemistry, 2006, 52, 1138-1143.	1.5	129
5	Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1077-80.	1.4	103
6	Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clinical Biochemistry, 2007, 40, 1398-1405.	0.8	93
7	The Analytical Goals for Hemoglobin A1c Measurement in IFCC Units and National Glycohemoglobin Standardization Program Units Are Different. Clinical Chemistry, 2011, 57, 1204-1206.	1.5	75
8	The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetologica, 2012, 49, 153-160.	1.2	61
9	Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clinica Chimica Acta, 2011, 412, 1412-1416.	0.5	46
10	EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. Clinical Chemistry, 2018, 64, 1183-1192.	1.5	46
11	The relevance of hemoglobin F measurement in the diagnosis of thalassemias and related hemoglobinopathies. Clinical Biochemistry, 2009, 42, 1797-1801.	0.8	44
12	PDCD10 Gene Mutations in Multiple Cerebral Cavernous Malformations. PLoS ONE, 2014, 9, e110438.	1.1	41
13	New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia. Bioelectrochemistry, 2008, 73, 137-140.	2.4	33
14	Evaluation of biological variation of glycated albumin (GA) and fructosamine in healthy subjects. Clinica Chimica Acta, 2013, 423, 1-4.	0.5	33
15	Glycemic control in the clinical management of diabetic patients. Clinical Chemistry and Laboratory Medicine, 2013, 51, 753-766.	1.4	31
16	External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clinical Chemistry and Laboratory Medicine, 2007, 45, 88-92.	1.4	24
17	Biological Variability of Albumin Excretion Rate and Albumin-to-Creatinine Ratio in Hypertensive Type 2 Diabetic Patients. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1229-33.	1.4	21
18	Recommendations for the implementation of international standardization of glycated hemoglobin in Italy. Clinical Chemistry and Laboratory Medicine, 2010, 48, 623-626.	1.4	20

#	Article	IF	Citations
19	Performance of glycated hemoglobin (HbA1c) methods evaluated with EQAS studies using fresh blood samples: Still space for improvements. Clinica Chimica Acta, 2015, 451, 305-309.	0.5	19
20	Effectiveness of citrate buffer-fluoride mixture in Terumo tubes as an inhibitor of in vitro glycolysis. Biochemia Medica, 2016, 26, 68-76.	1.2	18
21	Towards the development of a certified reference material for hemoglobin A₂. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1611-1618.	1.4	17
22	Multicenter evaluation of an enzymatic method for glycated albumin. Clinica Chimica Acta, 2017, 469, 81-86.	0.5	17
23	Developing a reference system for the IFCC standardization of HbA 2. Clinica Chimica Acta, 2017, 467, 21-26.	0.5	15
24	Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1315-20.	1.4	14
25	Analytical evaluation of the Tosoh HLC-723 G7 automated HPLC analyzer for hemoglobin A2 and F determination. Clinical Biochemistry, 2005, 38, 159-165.	0.8	12
26	Genetic variability of the fructosamine 3-kinase gene in diabetic patients. Clinical Chemistry and Laboratory Medicine, 2011, 49, 803-808.	1.4	12
27	Clinical Utility of Fractionating Erythrocytes into â€œPercollâ€•Density Gradients. Advances in Experimental Medicine and Biology, 1991, 307, 227-238.	0.8	11
28	Calibration by commutable control materials is able to reduce inter-method differences of current high-performance methods for HbA 2. Clinica Chimica Acta, 2018, 477, 60-65.	0.5	11
29	Determination of HbA2 by quantitative bottom-up proteomics and isotope dilution mass spectrometry. Clinica Chimica Acta, 2018, 487, 318-324.	0.5	11
30	Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. Cancers, 2020, 12, 1505.	1.7	11
31	Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia. Journal of Blood Medicine, 2011, 2, 23.	0.7	9
32	Analytical goals for the determination of HbA2. Clinical Chemistry and Laboratory Medicine, 2013, 51, 937-41.	1.4	9
33	Commutability of control materials in glycohemoglobin determinations. Clinical Chemistry, 1998, 44, 632-638.	1.5	8
34	An evaluation of the Diamat HPLC analyser for simultaneous determination of haemoglobins A2and F. Journal of Automated Methods and Management in Chemistry, 1989, 11, 273-279.	0.4	7
35	A roadmap for the standardization of hemoglobin A2. Clinica Chimica Acta, 2021, 512, 185-190.	0.5	7
36	Inter-Method Differences and Commutability of Control Materials for HbA2 Measurement. Clinical Chemistry and Laboratory Medicine, 2000, 38, 997-1002.	1.4	6

#	Article	IF	Citations
37	Experiences in the measurement of RBC-bound IgG as markers of cell age. Bioelectrochemistry, 2004, 62, 175-179.	2.4	6
38	Feasibility of an EQAS for HbA1c in Italy using fresh blood samples. Clinical Chemistry and Laboratory Medicine, 2014, 52, e151-3.	1.4	6
39	Glycation gap: An additional tool for glycometabolic monitoring. Clinica Chimica Acta, 2016, 463, 27-31.	0.5	6
40	Correct determination of glycemia in the diagnosis and management of diabetes: Recommendations for the optimization of the pre-analytical phase. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1-3.	1.1	5
41	Re-thinking diabetic nephropathy: Microalbuminuria is just a piece of the diagnostic puzzle. Clinica Chimica Acta, 2022, 524, 146-153.	0.5	5
42	Commutability of control materials in glycohemoglobin determinations. Clinical Chemistry, 1998, 44, 632-8.	1.5	5
43	Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM. BMJ Open Diabetes Research and Care, 2020, 8, e001256.	1.2	3
44	Why glycated albumin decreases in pregnancy? Evidences from a prospective study on physiological pregnancies of Caucasian women. Clinica Chimica Acta, 2021, 520, 217-218.	0.5	2
45	Reactivation of fetal hemoglobin in thalassemia and sickle cell disease. Thalassemia Reports, 2014, 4, .	0.1	1
46	Sources and performance criteria of uncertainty of reference measurement procedures. Clinical Biochemistry, 2018, 57, 29-36.	0.8	1
47	The analytical performance of laboratory plasma glucose and HbA1c measurements are largely acceptable. Acta Diabetologica, 2020, 57, 215-219.	1.2	1
48	Standardization of the HbA Assay. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 298-302.	0.7	1
49	Reference Intervals for Acetylated Fetal Hemoglobin in Healthy Newborns. Thalassemia Reports, 2014, 4, 2120.	0.1	0